Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Early Assessment of Lymphoma Therapeutic Efficacy Via a Blood-Based Multi-Omics Test

Xinhua Wang, Zhiming Li, Yu Chang, Shiyong Li, Wei Wu, Fangyuan Chang, Yinyin Chang, Dandan Zhu, Mingzhi Zhang, Mao Mao

Blood (2024) 144 (Supplement 1): 4987.

https://doi.org/10.1182/blood-2024-202715

Published: 2024

Journal Articles

Daunorubicin and Cytarabine 3+5 Combined with Venetoclax in De Novo Patients with Acute Myeloid Leukemia: A Single-Center, Open-Label, Controlled Study

Zhenqi Huang, Xinyi Dong, Wei Wu, Min Ruan, Jian Ge, Zhangbiao Long

Blood (2024) 144 (Supplement 1): 6048.

https://doi.org/10.1182/blood-2024-210856

Published: 2024

Journal Articles

Wilms' Tumor 1 Functions As a Tumor Suppressor to Suppress FLT3-STAT Signaling and Epigenetic Remodeling in Acute Myeloid Leukemia (CALGB 8461, 9665 and 20202; Alliance)

Blood (2023) 142 (Supplement 1): 4126.

https://doi.org/10.1182/blood-2023-188892

Published: 2023

Journal Articles

A Single Center Real World Study of Outcome and Resistance of Bruton Tyrosine Kinase Inhibitors (BTKi) in Chinese Patients with Chronic Lymphocytic Leukeima/Small Lymphocytic Lymphoma

Huayuan Zhu, Luomengjia Dai, Yeqin Sha, Xiao Lu, Siqi Qian, Tonglu Qiu, Yi Miao, Yi Xia, Shuchao Qin, Ziyuan Zhou, Wei Wu, Lei Fan, Wei Xu, Jianyong Li

Blood (2023) 142 (Supplement 1): 4653.

https://doi.org/10.1182/blood-2023-189681

Published: 2023

Journal Articles

Efficacy and Safety of Low-Dose Venetoclax Combined with Voriconazole Inpatients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy

Danchen Meng, Min Ruan, Xinyao Liu, Wei Wu, Junling Zhuang, Jian Ge, Zhenqi Huang, Zhangbiao Long

Blood (2023) 142 (Supplement 1): 5968.

https://doi.org/10.1182/blood-2023-184866

Published: 2023

Journal Articles

High Rates of Remission with the Initial Treatment of Oral Selinexor Plus CHOP for Newly Diagnosed Peripheral T-Cell Lymphoma (PTCL): Clinical Outcomes Analysis of a Multi-Center Phase II Study in China

Kaiyang Ding, Jie Ma, Xiaohui Zhang, Chunling Wang, Huang Hongming, Lixia Sheng, Hailing Liu, Lei Cao, Wei Wu, Jianyong Li, Lei Fan

Blood (2023) 142 (Supplement 1): 1696.

https://doi.org/10.1182/blood-2023-182553

Published: 2023

Journal Articles

Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study)

Huayuan Zhu, Yi Miao, Yi Xia, Shuchao Qin, Wei Wu, Tonglu Qiu, Chong-Yang Ding, Hairong Qiu, Chun Qiao, Yujie Wu, Fei Li, Wei Xu, Jianyong Li

Blood (2023) 142 (Supplement 1): 4642.

https://doi.org/10.1182/blood-2023-188925

Published: 2023

Journal Articles

A Real-World Study of Zanubrutinib Treatment in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Huayuan Zhu, Yi Xia, Yi Miao, Shuchao Qin, Wei Wu, Tonglu Qiu, Li Wang, Lei Fan, Wei Xu, Jianyong Li

Blood (2023) 142 (Supplement 1): 6554.

https://doi.org/10.1182/blood-2023-189110

Published: 2023

Journal Articles

Aging alters the cell cycle control and mitogenic signaling responses of human hematopoietic stem cells

Colin A. Hammond, Si Wei Wu, Fangwu Wang, Margarita E. MacAldaz, Connie J. Eaves

Blood (2023) 141 (16): 1990–2002.

https://doi.org/10.1182/blood.2022017174

Published: 2023

Includes: Supplemental data

Journal Articles

Single-Cell RNA Sequencing Reveals the Characteristics of High Proliferating Tumor Cells in Btki-Resistant Progression to Richter Transformation and Accelerated CLL

Yeqin Sha, Shuchao Qin, Yi Miao, Rui Jiang, Wei Wu, Yi Xia, Tonglu Qiu, Li Wang, Lei Fan, Wei Xu, Hui Jin, Jianyong Li, Huayuan Zhu

Blood (2022) 140 (Supplement 1): 6992–6993.

https://doi.org/10.1182/blood-2022-169907

Published: 2022

Journal Articles

Prompt Assessment of Tumor Load and Treatment Response in Patients with Lymphoma By a Blood-Based Multi-Omics Approach

Xinhua Wang, Zhiming Li, Yu Chang, Shiyong Li, Wei Wu, Fangyuan Chang, Yinyin Chang, Dandan Zhu, Mingzhi Zhang, Mao Mao

Blood (2022) 140 (Supplement 1): 6415–6416.

https://doi.org/10.1182/blood-2022-165642

Published: 2022

Journal Articles

Amplifying Sting Activation By Bio-Inspired Nanomedicine for Targeted Acute Myeloid Leukemia Chemo- and Immunotherapy

Xiaoqi Wang, Ruihao Huang, Wei Wu, Jingkang Xiong, Qin Wen, Yunjing Zeng, Ting Chen, Jiali Li, Cheng Zhang, Jiang F. Zhong, Shijie Yang, Xi Zhang

Blood (2022) 140 (Supplement 1): 7804–7805.

https://doi.org/10.1182/blood-2022-169445

Published: 2022

Journal Articles

Integrating Multi-Omics to Reveal the Clonal Evolutionary Characteristics in CLL Patients with Zanubrutinib Resistance

Huayuan Zhu, Yeqin Sha, Yi Miao, Shuchao Qin, Rui Jiang, Wei Wu, Yi Xia, Tonglu Qiu, Li Wang, Lei Fan, Wei Xu, Hui Jin, Jianyong Li

Blood (2022) 140 (Supplement 1): 6985–6987.

https://doi.org/10.1182/blood-2022-169720

Published: 2022

Journal Articles

Targeting the WT1 mut -M ir-193a Transcriptional Axis with INT-1B3, a Novel Lipid Nanoparticle-Formulated Mir -193a-3p Mimic in Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 6224–6225.

https://doi.org/10.1182/blood-2022-157833

Published: 2022

Journal Articles

Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab As Inital Treatment for Chronic Lymphocytic Leukemia/ Small Lymphocytic Leukemia

Huayuan Zhu, Yeqin Sha, Yi Miao, Shuchao Qin, Hui Shen, Jingyan Qiu, Wei Wu, Yi Xia, Tonglu Qiu, Li Wang, Lei Fan, Wei Xu, Jianyong Li

Blood (2022) 140 (Supplement 1): 4164–4165.

https://doi.org/10.1182/blood-2022-170815

Published: 2022

Journal Articles

Novel BTK Mutations Conferring Resistance to the Second-Generation, Irreversible BTK Inhibitor Orelabrutinib (ICP-022)

Huayuan Zhu, Yeqin Sha, Yi Miao, Shuchao Qin, Wei Wu, Yi Xia, Tonglu Qiu, Li Wang, Lei Fan, Wei Xu, Jianyong Li

Blood (2022) 140 (Supplement 1): 4117–4118.

https://doi.org/10.1182/blood-2022-170985

Published: 2022

Journal Articles

Genetic and phenotypic attributes of splenic marginal zone lymphoma

Ferdinando Bonfiglio, Alessio Bruscaggin, Francesca Guidetti, Lodovico Terzi di Bergamo, Martin Faderl, Valeria Spina, Adalgisa Condoluci, Luisella Bonomini, Gabriela Forestieri, Ricardo Koch, Deborah Piffaretti, Katia Pini, Maria Cristina Pirosa, Micol Giulia Cittone, Alberto Arribas, Marco Lucioni, Guido Ghilardi, Wei Wu, Luca Arcaini, Maria Joao Baptista, Gabriela Bastidas, Silvia Bea, Renzo Boldorini, Alessandro Broccoli, Marco Matteo Buehler, Vincenzo Canzonieri, Luciano Cascione, Luca Ceriani, Sergio Cogliatti, Paolo Corradini, Enrico Derenzini, Liliana Devizzi, Sascha Dietrich, Angela Rita Elia, Fabio Facchetti, Gianluca Gaidano, Juan Fernando Garcia, Bernhard Gerber, Paolo Ghia, Maria Gomes da Silva, Giuseppe Gritti, Anna Guidetti, Felicitas Hitz, Giorgio Inghirami, Marco Ladetto, Armando Lopez-Guillermo, Elisa Lucchini, Antonino Maiorana, Roberto Marasca, Estella Matutes, Veronique Meignin, Michele Merli, Alden Moccia, Manuela Mollejo, Carlos Montalban, Urban Novak, David Graham Oscier, Francesco Passamonti, Francesco Piazza, Stefano Pizzolitto, Alessandro Rambaldi, Elena Sabattini, Gilles Salles, Elisa Santambrogio, Lydia Scarfò, Anastasios Stathis, Georg Stüssi, Julia T. Geyer, Gustavo Tapia, Corrado Tarella, Catherine Thieblemont, Thomas Tousseyn, Alessandra Tucci, Giorgio Vanini, Carlo Visco, Umberto Vitolo, Renata Walewska, Francesco Zaja, Thorsten Zenz, Pier Luigi Zinzani, Hossein Khiabanian, Arianna Calcinotto, Francesco Bertoni, Govind Bhagat, Elias Campo, Laurence De Leval, Stefan Dirnhofer, Stefano A. Pileri, Miguel A. Piris, Alexandra Traverse-Glehen, Alexander Tzankov, Marco Paulli, Maurilio Ponzoni, Luca Mazzucchelli, Franco Cavalli, Emanuele Zucca, Davide Rossi

Blood (2022) 139 (5): 732–747.

https://doi.org/10.1182/blood.2021012386

Published: 2022

Includes: Supplemental data

Journal Articles

Venetoclax Combined with Dose-Adjusted R-EPOCH (VR-DA-EPOCH) As Treatment of Richter's Syndrome: A Real-World Study

Huayuan Zhu, Rui Jiang, Hui Shen, Wei Wu, Yilian Yang, Chen Peng, Jingyan Qiu, Chongyang Ding, Chuanbing Shi, Ruize Chen, Li Wang, Lei Fan, Wei Xu, Jianyong Li

Blood (2021) 138 (Supplement 1): 4695.

https://doi.org/10.1182/blood-2021-152483

Published: 2021

Journal Articles

BTK Inhibitor Ibrutinib/Zanubrutinib Plus Bendamustine and Rituximab As the Initial Treatment for Chronic Lymphocytic Leukemia/ Small Lymphocytic Leukemia：a Single Arm Real-World Study

Huayuan Zhu, Wei Wu, Yeqin Sha, Ze Jin, Yilian Yang, Jingyan Qiu, Chongyang Ding, Zhen Wang, Chuanbing Shi, Chen Peng, Hongling Mi, Ruize Chen, Li Wang, Lei Fan, Wei Xu, Jianyong Li

Blood (2021) 138 (Supplement 1): 4697.

https://doi.org/10.1182/blood-2021-152147

Published: 2021

Journal Articles

The Interim Efficacy of Epigenetic Priming Regimen with Azacytidine and Chidamide in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma

Kaiyang Ding, Xiao Shi, Haiyan Yang, Lei Cao, Xiaoli Zhao, Hailing Liu, Wei Wu, Xiaoyan Zhang, Li Wang, Wei Xu, Huayuan Zhu, Jianyong Li, Lei Fan

Blood (2021) 138 (Supplement 1): 2461.

https://doi.org/10.1182/blood-2021-150523

Published: 2021

NARROW

Early Assessment of Lymphoma Therapeutic Efficacy Via a Blood-Based Multi-Omics Test

Daunorubicin and Cytarabine 3+5 Combined with Venetoclax in De Novo Patients with Acute Myeloid Leukemia: A Single-Center, Open-Label, Controlled Study

Wilms' Tumor 1 Functions As a Tumor Suppressor to Suppress FLT3-STAT Signaling and Epigenetic Remodeling in Acute Myeloid Leukemia (CALGB 8461, 9665 and 20202; Alliance)

A Single Center Real World Study of Outcome and Resistance of Bruton Tyrosine Kinase Inhibitors (BTKi) in Chinese Patients with Chronic Lymphocytic Leukeima/Small Lymphocytic Lymphoma

Efficacy and Safety of Low-Dose Venetoclax Combined with Voriconazole Inpatients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy

High Rates of Remission with the Initial Treatment of Oral Selinexor Plus CHOP for Newly Diagnosed Peripheral T-Cell Lymphoma (PTCL): Clinical Outcomes Analysis of a Multi-Center Phase II Study in China

Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study)

A Real-World Study of Zanubrutinib Treatment in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Aging alters the cell cycle control and mitogenic signaling responses of human hematopoietic stem cells

Single-Cell RNA Sequencing Reveals the Characteristics of High Proliferating Tumor Cells in Btki-Resistant Progression to Richter Transformation and Accelerated CLL

Prompt Assessment of Tumor Load and Treatment Response in Patients with Lymphoma By a Blood-Based Multi-Omics Approach

Amplifying Sting Activation By Bio-Inspired Nanomedicine for Targeted Acute Myeloid Leukemia Chemo- and Immunotherapy

Integrating Multi-Omics to Reveal the Clonal Evolutionary Characteristics in CLL Patients with Zanubrutinib Resistance

Targeting the WT1 mut -M ir-193a Transcriptional Axis with INT-1B3, a Novel Lipid Nanoparticle-Formulated Mir -193a-3p Mimic in Acute Myeloid Leukemia

Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab As Inital Treatment for Chronic Lymphocytic Leukemia/ Small Lymphocytic Leukemia

Novel BTK Mutations Conferring Resistance to the Second-Generation, Irreversible BTK Inhibitor Orelabrutinib (ICP-022)

Genetic and phenotypic attributes of splenic marginal zone lymphoma

Venetoclax Combined with Dose-Adjusted R-EPOCH (VR-DA-EPOCH) As Treatment of Richter's Syndrome: A Real-World Study

BTK Inhibitor Ibrutinib/Zanubrutinib Plus Bendamustine and Rituximab As the Initial Treatment for Chronic Lymphocytic Leukemia/ Small Lymphocytic Leukemia：a Single Arm Real-World Study

The Interim Efficacy of Epigenetic Priming Regimen with Azacytidine and Chidamide in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only